• The srd a isoforms showed unique

  2022-11-04

  

  The srd5a isoforms showed unique expression profiles in early FHM development (Fig. 2). Similar to amphibian embryos, there was a high abundance of both srd5a1 and srd5a3 at 1dpf in FHMs, suggesting that mRNA for these enzymes may be maternally deposited and that these enzymes may play a key role i

• In addition to the data provided by the Ki

  2022-11-04

  

  In addition to the data provided by the Ki16425 treatment in the K/BxN arthritis model, new findings from the study of two new LPA receptor antagonists confirm the involvement of the LPA pathway in the pathogenesis of experimental arthritis. In the study by Miyabe et al., the authors reported the tr

• Evidence from basic science studies suggests that

  2022-11-03

  

  Evidence from basic science studies suggests that Cd may play a role in prostate cancer through disruption of the androgen receptor (AR). AR, a hormone-activated transcription factor, is the key driver of prostate cancer progression [6]. Ironically, the AR is also required for normal prostate growth

• br AR signals and chemosensitivity in urothelial cancer

  2022-11-03

  

  AR signals and chemosensitivity in urothelial cancer A significant amount of patients with urothelial cancer fail to respond to cisplatin-based systemic chemotherapy, although it remains the mainstay of successful management of advanced disease. However, underlying mechanisms for chemoresistance

• There are several reports providing evidences

  2022-11-03

  

  There are several reports providing evidences that functional and mechanistic connection between Sirt1 and LKB1/AMPK in metabolic regulation [26], [32], [33]. It has been reported that the deacetylation of LKB1 by Sirt1 is one of the determining factors of the subcellular localization of LKB1. In ag

• br Results br Discussion By using an unbiased proteomic

  2022-11-03

  

  Results Discussion By using an unbiased proteomic screen for xCT binding partners, followed by functional validation, we have made the surprising discovery that mTORC2 regulates amino Bupivacaine HCl sale metabolism in tumor cells by phosphorylating serine 26 of the cystine-glutamate antiport

• So far many independent studies have linked

  2022-11-03

  

  So far, many independent studies have linked cholesterol metabolism–related genes with AD, either by showing associations with specific polymorphisms or with differential valdecoxib mg levels (Beecham et al., 2014, Blain and Poirier, 2004, Lambert et al., 2009, Lambert et al., 2013, Leduc et al., 2

• valeriana te Aberrant or a sustained activation of AhR signa

  2022-11-03

  

  Aberrant or a sustained activation of AhR signaling pathway, triggered by exogenous toxic ligands such as dioxins, PAHs or polychlorinated biphenyls (PCBs), is a well-described biological process engaged during tumor initiation and/or promotion in various tissues (e.g. liver, lung, skin)(reviewed in

• The putative physiological meaning of

  2022-11-03

  

  The putative physiological meaning of epinephrine-related hepatic drug transporter regulation remains to be established. It is nevertheless noteworthy that the catecholamine rather decreases expression of sinusoidal SLC transporters like NTCP, OAT2, OAT7, OCT1, OATP1B1 and OATP2B1 whereas those of c

• In vitro studies with soman inhibited non

  2022-11-03

  

  In vitro studies with soman-inhibited, non-aged AChE revealed a species dependent reactivating potency of HI-6 and MMB-4. With guinea pig AChE second order reactivation rate constants of 0.051 and 0.038mM−1min−1 were determined for HI-6 and MMB-4, respectively (Luo et al., 2007). Corresponding value

• br AD and COX LOX pharmacology Early studies

  2022-11-03

  

  AD and COX/5-LOX pharmacology Early studies on the role of cyclooxygenases in AD were inspired by epidemiological data suggesting that COX inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs) could be beneficial in AD patients (Lucca et al., 1994, McGeer et al., 1990). This line of re

• For the NSCLC patients with EGFR

  2022-11-03

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

• In conclusion AXL overexpression preexisted in a subgroup

  2022-11-03

  

  In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi

• Here the so called alkali assay is proposed as

  2022-11-03

  

  Here the so-called alkali assay [18] is proposed as a method to be applied directly on the purified recombinant enzyme sharing the same structural and functional features of the wild-type enzyme [19], [20], [21] using its physiological substrate androstenedione. The assay that was already successful

• 221 2 We found a protective effect of the GTCC haplotype

  2022-11-03

  

  We found a protective effect of the GTCC haplotype against ED, which is reflected by its association with increased IIEF in patients with clinical ED. Further studies are required to determine the functional implications of these genetic markers combined in specific haplotypes blocks. Indeed, we fou

15626 records 349/1042 page Previous Next First page 上5页 346347348349350 下5页 Last page